Abstract:Inflammatory bowel disease (IBD) is a complex and chronic inflammatory disease that is challenging to be cured and prone to carcinogenesis. Existing medications for IBD have limited efficacy and often come with adverse effects, which necessitates the development of new therapies. Clostridium butyricum and its metabolite, butyrate, have recently been identified as a probiotic and a metabolite, respectively, that offer protective benefits to the intestinal mucosal barrier. However, the specific mechanisms underlying their actions remain to be elucidated. Therefore, this article comprehensively reviews the research progress in the roles of C. butyricum and butyrate in the pathogenesis of IBD via influencing the intestinal barrier function, as well as their potential clinical values in the treatment of IBD. The findings will give novel insights into the research on the pathogenesis and innovation of the therapies of IBD.
